Pfizer Future Growth
Future criteria checks 1/6
Pfizer se prevé un crecimiento anual de los beneficios y los ingresos de 14.5% y 8.1% respectivamente. Se prevé que el BPA sea de grow en 14.5% al año. Se prevé que la rentabilidad de los fondos propios sea de 16.4% en 3 años.
Key information
14.5%
Earnings growth rate
14.5%
EPS growth rate
Pharmaceuticals earnings growth | 18.9% |
Revenue growth rate | 8.1% |
Future return on equity | 16.4% |
Analyst coverage | Low |
Last updated | 20 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 26,332 | 6,803 | 4,901 | N/A | 3 |
3/31/2025 | 23,806 | 5,878 | 4,631 | N/A | 3 |
3/31/2024 | 22,007 | 5,015 | 5,028 | N/A | 3 |
12/31/2023 | 22,192 | 5,021 | N/A | N/A | N/A |
9/30/2023 | 23,010 | 5,228 | 4,322 | 5,040 | N/A |
6/30/2023 | 23,632 | 6,849 | N/A | N/A | N/A |
3/31/2023 | 24,248 | 6,239 | 2,907 | 3,557 | N/A |
12/31/2022 | 24,041 | 6,201 | N/A | N/A | N/A |
9/30/2022 | 24,583 | 6,133 | 1,341 | 1,493 | N/A |
6/30/2022 | 24,571 | 4,452 | N/A | N/A | N/A |
3/31/2022 | 26,110 | 6,126 | 6,518 | 6,671 | N/A |
12/31/2021 | 25,961 | 5,873 | N/A | N/A | N/A |
9/30/2021 | 25,137 | 5,847 | 7,018 | 7,147 | N/A |
6/30/2021 | 24,728 | 5,731 | N/A | N/A | N/A |
3/31/2021 | 22,404 | 4,976 | 4,096 | 4,273 | N/A |
12/31/2020 | 22,058 | 5,001 | N/A | N/A | N/A |
9/30/2020 | 21,505 | 4,979 | 4,129 | 4,004 | N/A |
6/30/2020 | 21,221 | 5,208 | N/A | N/A | N/A |
3/31/2020 | 21,517 | 5,091 | 3,211 | 3,232 | N/A |
12/31/2019 | 21,853 | 5,156 | N/A | N/A | N/A |
9/30/2019 | 21,609 | 5,085 | 1,760 | 1,716 | N/A |
6/30/2019 | 21,136 | 4,500 | N/A | N/A | N/A |
3/31/2019 | 20,815 | 4,291 | 1,245 | 978 | N/A |
12/31/2018 | 20,658 | 4,241 | N/A | N/A | N/A |
9/30/2018 | 20,085 | 3,794 | N/A | N/A | N/A |
6/30/2018 | 20,599 | 3,947 | N/A | N/A | N/A |
3/31/2018 | 19,685 | 3,601 | 2,291 | 3,318 | N/A |
12/31/2017 | 18,866 | 3,236 | N/A | N/A | N/A |
9/30/2017 | 19,215 | 2,987 | N/A | N/A | N/A |
6/30/2017 | 18,860 | 3,139 | N/A | N/A | N/A |
3/31/2017 | 19,663 | 3,368 | N/A | 3,288 | N/A |
12/31/2016 | 20,453 | 2,737 | N/A | N/A | N/A |
9/30/2016 | 20,595 | 2,711 | N/A | N/A | N/A |
6/30/2016 | 20,350 | 2,276 | N/A | N/A | N/A |
3/31/2016 | 20,123 | 3,050 | N/A | 3,455 | N/A |
12/31/2015 | 19,649 | 1,680 | N/A | N/A | N/A |
9/30/2015 | 19,334 | 1,460 | N/A | N/A | N/A |
6/30/2015 | 19,018 | 861 | N/A | N/A | N/A |
3/31/2015 | 18,531 | 698 | N/A | 1,135 | N/A |
12/31/2014 | 16,632 | 1,137 | N/A | N/A | N/A |
9/30/2014 | 11,078 | 1,380 | N/A | N/A | N/A |
6/30/2014 | 11,118 | 2,194 | N/A | N/A | N/A |
3/31/2014 | 11,103 | 2,209 | N/A | 1,324 | N/A |
12/31/2013 | 11,161 | 2,230 | N/A | N/A | N/A |
9/30/2013 | 11,002 | 2,393 | N/A | N/A | N/A |
6/30/2013 | 10,736 | 2,220 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: 500680(14.5% al año) es superior a la tasa de ahorro (6.7%).
Beneficios frente mercado: 500680Se prevé que los beneficios de la empresa (14.5% al año) crezcan menos que el mercado Indian (17.8% al año).
Beneficios de alto crecimiento: 500680Se prevé que los beneficios de la empresa crezcan, pero no significativamente.
Ingresos vs. Mercado: 500680(8.1% al año) se prevé que crezca más despacio que el mercado de Indian (10.5% al año).
Ingresos de alto crecimiento: 500680Se prevé que los ingresos de la empresa (8.1% al año) crezcan más despacio que 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): 500680Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (16.4%).